Good morning, ladies and gentlemen, and welcome to this morning's, webinar. My name is Maria Halasz, and I am the CEO of Genetic Signatures.

With me today is Angie Wang, who is our Head of Finance, and, Angie is joining us for the first time. She has recently been promoted, and this is her first annual audit and financial results release, and the fact that she became quite ill recently right after we released the result has nothing to do with the stress that she may have been under during the course of the audit.

With that in mind, I would like to just, note the order for today. The order will be that I'll make a short presentation on the actual results, following which we will open up for questions, and you'll be able to ask.

We have had some questions, that have been submitted prior to the meeting, and I will start, by answering those questions and then open it for the forum. Obviously, today's topic is the financial research results for, the 2026 financial year.

What we'll be talking about is really, first, I just want to recap on, about Genetic Signatures and the real advantages all around the company's assets, our product portfolio, and, generally where we sit on the market. I will talk about a little bit about the highlights from the financial year, the actual results, some of the key things that we've achieved since I've, started in March this year, including this the progress we've made on the growth strategy that we've announced on the 10th of June.

Finally, I'll talk through some of the outlook and some what what we see coming in the coming months. Just to recap, we are a respiratory and enteric multiplex PCR solution provider.

In addition to these portfolios, product portfolios, we have, molecular diagnostics assays, and those will be either, regulatory approved by the TGA, FDA, or CE marked. We also have a research use only products.

We manufacture all our products in Australia in our Maroubra facility under the EasyScreen, brand name, and we sell them in, US, Europe, and in Australia. We have, distribution partnerships through Europe.

We sell direct in the UK and in Australia and in the US. What are the key benefits of our products or to generally just molecular diagnostics?

Certainly, our 3base, technology in provides improved sensitivity, specificity, and reliability when it comes to detection of infective infectious pathogens. We obviously support, antimicrobial stewardship in hospitals and, GP practices.

We provide, an increased pathogen cover coverage of up to up to 24 pathogens per panel. We provide a multiplex, solution to our back labs and hospital labs.

Particularly in hospitals, when they use our products, we see a reduction in patient per bed and an increase in patient flow, which is of course, a significant health economic benefit. Obviously, it, contributes to reduced labor and stress within those working environments for, the the health, professionals that provide those services.

For the hospitals and for the health economy generally, it provides efficiencies. Just to flash on the market, and we are obviously in the syndromic testing market, and, we see that, type of testing grow across, various regions globally.

It's very much, driven by, the demand that up from population growth. Obviously, there is an increase infectious disease prevalence.

And, increasingly, geographies are more and more awa- aware of multiple text that, the advantages of multiplex testing. Reduced net, $14 million from last year.

Our cash outflow was down, to $7 million, down from $12.3 million. And, we closed the financial year on the 30th of June 2026 with 20 22 $2.1 million cash remaining.

We've reported since that our current cash is $21.3 million. We're managing, we continue to manage our cash flo- cash flow very prudently.

In terms of our revenues, they were $14.8 million, and it's slightly down by 7% the prior ye- year. That was a result of a couple of things.

One is, we faced increased competition, which is the nature of any business and particularly molecular diagnostics. In addition to that, we've observed a delayed and muted flu season this year.

Last year, we had a very intense flu season, a lot more testing and a lot more positive cases. This year, positive cases in Australia have been down by 73%, and, as a consequence, people probably also tested less.

In terms of the organizational restructure, we've completed that in April, and we expect that in 2027, we'll see an annual cost saving of about $5 million as a result of that. We're already beginning to see that, certainly in the last, 3 months in the FY 2026 financial year.

We've seen that that those kind of savings have been coming down into the bottom line. What we've also done in April is we signed a 10-year supply agreement with Hvidovre Hospital in Denmark, and, we have since, successfully completed in situ validation and received our first commercial order.

The actual testing has commenced as well in August. We've secured all our long-term supply agreements, we've we've got a very secure annualized revenue that we can expect in the coming years.

We have completed a comprehensive organizational review, the result of which was a 3-horizon resetting of the business, which we've announced on the 10th of June this year. Let's talk about numbers.

Obviously, I've mentioned our revenue was down 7% for a variety of reasons. Our cost of materials have gone up slightly.

Our net operating cash outflow was also down by 37%, and of course net loss was down 30%, $14 million. All this are really important because what we're doing is we're securing, operational runway for us to really sit that to reset the business.

In terms of employee expenses in FY 2026, they were reduced by 16%, and that's just the beginning of what we see as a result of the organizational restructure. Of course, our cash balance is remaining strong at $22.1 million.

In fact, as we release, 20 $1.3 as of the release of that report on the 25th of August. Some key highlights and a little bit more color around what we've done.

The first thing we had have to really do is really review where the organization is and be pretty frank about, what we had to do to make sure that we secure the business and we reset it for growth. As part of that, we've completed a resizing or right-sizing of the company.

We've done a line-by-line review of expenditure, and overall we expect that will come down to a cost savings of about $5 million in in this current financial year. That comes on the back of establishing very strict purchasing processes and controls.

We've been very prudent in the way we deploy capital, and again that is something that we're beginning to see on our cash flows. We've also set up an AI policy, and we expect productivity gains like everyone else on the market.

It's very difficult for us to measure productivity, but we've got at least 2 areas where we're already seeing that AI enablement actually facilitates the business. Certainly in administrative functions we're already seeing that, but in addition to that, in our regulatory function we're where we've been able to utilize AI to to develop and file a lot of our regulatory work.

All of this resulted in an inki- increase cash runway, as I mentioned before. We've also secured our long-term supply agreement.

Hvidovre Hospital was a real win for our EMEA team. This has been in the making for a few months.

Obviously, these, these agreements take a few months to secure. Following the signing of the contract, the team actually successfully validated and started commercial testing, which was a key milestone for the contract to be active.

We've done the same in Australia in terms of securing long-term supply agreements. And, we've also implemented 2 product upgrades, and that will just allow us to deliver our services much better to our current customers.

We've also reviewed our instrumentation strategy. Obviously, the way we deliver our products is through, deliver- delivering, proba- robot- providing robotics equipment to our customers.

Our our equipment, obviously is under constant upgrade, and so we've reviewed our next-generation instrument requirements. And, we paused a a an instrument development program that was really focused around a highly customized, solution.

Instead, we've looked around the market, and, we've developed a, or we've devel- developed a strategy to access off-the-shelf, solutions. Not only this will be faster to deliver, more cost effective, but really brings us into the into the 2026 and beyond as far as robotics is concerned.

In on the 10th of June, we've announced our growth strategy, which, rested on 3 horizons. Up to August this year, we wanted to stabilize the business.

In the next 12 months, we want to optimize our assets and resources to then set ourselves up for growth and then, proceed to scale the business. In terms of of what we've announced and what we've achieved, we've actually completed the Horizon 1, which is around tab- stabilizing a business.

We've obviously implemented the organizational restructure. We've separately announced that with the details.

Reviewed our product strategy and started 2 new product development programs, both of those on the back of strong internal intellectual property R&D, and they'll be a differentiated products on the market that will assist us both in terms of increasing sales, but also improving, delivery of service and products to our customers. We've we've signed our Australian contracts, and also we have reviewed our market access strategy in the various geographies we've been active, both in the US, EMEA, and of course in Australia.

I've discussed quite a bit around the implementation of financial controls that goes through the entire organization, and we put in, systems in place for how we deploy capital from very small amounts up to large amounts. They're very clear, delegations of authorities and controls to make sure that every cent that we spend is we understand how the return will come back from that.

We've also have finalized a a a product strategy and and and, corporate strategy, as we've released. As I mentioned earlier, we paused the customized instrumentation development, and we are now well in progress of, identifying or finalizing a an alternative off-the-shelf instrumentation solution.

We have also, developed our APAC market access strategy. Recently appointed our head of APAC for market access, who's already well in a job of delivering that market for us.

In terms of, other things we've announced in the 3-horizon strategy under the optimize, second phase was build a culture of excellence, and I can, genuinely say that the organization's strengths are its people. We've got an amazing, team that is now, fully committed to delivering organizational goals.

We've also, said, during the the strategic release that we're looking for partnerships. If you've been, looking at the announcements today, you may have seen that, we are announced that we're in discussions with Microba, around a potential corporate, transaction.

We In terms of scaling, we've not we're not suggesting that we do that until March, but we're well in advance in planning or progressing at various stages, and that's all around APAC. Obviously, that will be a medium-term, outcome for us.

As I mentioned before, we're progressing well on that. In terms of new product launches, we again expect that from early next year, we will be able to launch, our first product and later on in the year, the second.

We have had, a a substantial gain when we signed the Hvidovre contract in Europe this year in terms of penetrating the market on in in an area of infection prevention and control. We plan to progress on that, and we are, in discussions with a number of hospitals in the UK to broaden our market penetration there.

I mentioned about our long-term instrumentation strategy. Again, we're well in progress, and but as a result, we expect that a we bring our instrumentation strategy to the back to the future much faster and at much more cost-effective, way.

We've had some questions around, US the US market. We paused the US market, and the reason for that was simply to reassess what would be the most effective market access.

It's no secret that we have not achieved the traction we we wanted to achieve in that market. That was There was a multiple of reasons why that happened, not not the least that the market is moving very, very quickly.

It's a very advanced market. We want to make sure that when we actually s-, spend significant amounts in the US, it will We will get the r- return on that.

We have not yet commenced a new strategy in the US. However, we've got 3 active sites, and, the recent pit- pit- [Pemberton's spores is?]

outbreak in the US showed us that our product is unique, our product is very valuable as we saw some revenue coming out of the US as a result of utilizing our assays there. This is my final slide on the outlook.

Obviously, we're very intent on growing revenue on the o- our s- stabilized business. With our, solid long-term supply agreements, we've got, annual, reliable revenues coming to the company for several years.

And, we are also well placed to grow on that, given improving customer relationships. Very much focused on profitability.

We can't predict when that occurs as yet because there are too many variables, but we are constantly working both on the revenue increase and also on the on the margi- margin discipline side to achieve that objective. We also said that we're going to be, changing our business model from a fully in-house development to an outsourced, mixed model.

As part of that, we continue to, develop one of our products fully outsourced to limit our product risk, that might occur if we develop everything inside and given the, more constrained internal resources following the restructure. We will very We are very much intent on continuing our disciplined capital deployment.

As I mentioned, we watch every dollar. We've got very strict processes in place.

AI is very helpful in this for us. We can really monitor where our money is going and how our money is returning.

We're also pursuing new growth opportunities. Obviously, APAC is an opportunity that we want to explore further and EMEA with our infection prevention and control value proposition for hospitals, is coming through strong, and we expect, growth from there as well.

Finally, we will continue to focus on partnerships. That the doesn't just include corporate part- partnership, which you may have seen this morning's announcement, but it also includes manufacturing, product development, and, distribution and instrumentation partnerships, which we're actively pursuing, with various groups.

We're looking at renegotiating our contracts to be more cost effective. We're looking at more volume-based pricing for our partners, and we're really making sure that, the current terms of our agreements are reflective of the substantial value we ourselves as a business, provide to third-party, vendors.

With that, I close the actual presentation. I thank you for your attention, and I will start by answering some of the questions we have received prior to the presentation.

One question is, "Do any more contracts look like being signed in the US?" As I mentioned, we paused, further expansion in the US until we crystallize our a a more effective market access strategy, and we haven't commenced that yet.

However, we're actively supporting our current sites, and whilst we're not seeing new sites being immediately signed, we may see, revenue continuing to coming through from those sites. Then we've got, another question, "I am interested to know what the communication has been between GSS and BKL."

We I'm not aware of any communications between our companies at this stage, but again, I'm speaking from the management perspective. I've not been advised by the board that there are any com-, discussions between the companies at this stage.

There's the question about, "Why have they scaled back from the US?" As I've mentioned before, there were a number of reasons.

There've been changes to both the regulatory environment, market dynamics, new competi- competitors, and also a shift in the way, diagnostics are delivered. We had to reassess whether we're doing the right thing, we're offering the right solution to customers there, and as a result we've decided to pause, significant investment in the market because we just weren't certain that the results or the returns are going to come back to us.

Those are the questions we have received, and I'm going to go into the questions that we've we've received, online. If you don't wouldn't mind to give me a moment.

I might also ask, our head of finance, if needed, to address some of these questions herself. There's a question around, "What proportion of the $5 million cost savings in FY 2027 would have been eligible for R&D tax rebate?

Is the R&D taken into account in calculating the net savings?" Obviously, what we've done with the restructure is we really focused on development and market access as opposed to research in in, in the company, whilst we retained research capabilities that have been reduced.

Yes, the restructure will have an effect on our R&D tax rebate. Also, yes, we have actually calculated it into our net savings.

There's another question about, again, BKL, whether we've had any dis- discussions with them. We have not had any discussions with Biocartis at this stage.

I just saw the their change in substantial, shareholder notice this morning myself, and, I've not been advised by the board that there've been any discussions between the companies to date. "What would be the main rationale for a merger with Microba?"

I think, there's a number of things. One is there'd be a significant, corporate overhead savings between the companies.

Microba is in a in a, gut, health business, and, we also have an enteric, molecular diagnosis assays. To some extent, we both have a very strong businesses in that area, so that's a synergistic, part of our businesses.

I think, cer- there'd be significant savings around, around the corporate overheads, administrative costs. In terms of, the business itself, we potentially could, share distribution networks.

This is something that we're exploring currently further. Obviously, we've not done, nothing is finalized, and we really currently assessing this opportunity and in the middle of discussions with the companies.

So, we will be announcing anything else that, that will be material as the these discussions, develop. The next question is around around, "Expand on the 18% holding on by BDX and the merger talks with Microba."

I don't think I can add any more than what I've already added on both of those topics. We don't, to my, knowledge, I have not been advised by the board that there have been any conversations with BDX today.

And, in terms of Microba, our discussions are really just around assessing a corporate trans- transaction, and, we're doing, a a detailed review of what would be, whether that would be sensible, what would be the key advantages, quan- quantifying those advantages, and then coming back to the market with some more information once that's available. So, "Where do we see the main opportunities for revenue growth for us?"

In the short term, we see some of the And when I say short term, 12 to 18 months, certainly, a new product, increase in our current contracts, and, new contracts in EMEA and some revenue opportunities out of APAC, although these will be early and smaller. However, in a in a 2-year horizon and beyond, we see that APAC will provide us with the substantial growth opportunities.

Obviously, this is a this is a high-risk, part of our, belief system at the moment because we haven't been out there and actually delivering it. We've got a lot of confidence in both in terms of the team, products, and also the opportunity that might be there, and we have started conversations with, parties already in that market for, potential distribution of our products.

We see that in the short term, 12 to 18 months, it will be existing contracts, growth opportunities with new products, new new product launches, and then, as APAC is coming online, beyond that we'll see growth opportunities there in addition to new contracts in EMEA. We have quite a few questions on BKL and, Microba, and, again, I'm not going to be able to say anything more on that.

There is a question about, "Who is the right partner for Genetic Signatures, BDX, or MAP?" And, look, we we look at every opportunity to scale the business, and we will be making a making a recommendation to shareholders on the merits of each proposal that comes to us or each opportunity that we see and we want to pursue.

I wouldn't be able to, say which opportunity would be better at this stage. We certainly haven't done the the work, and we haven't done the discussions that would, merit a judgment on that or a judgment call on that for you.

I don't see any other questions at this stage. I think I've answered all of the 8 questions that were hit there.

I I note your interest, your deep interest on the on the announcements today, and because I'm not able to give any more information than one what is there at the moment and what I've already said, I think I'm going to close it there. And, thank you all who have attended.

I don't see any more questions coming through. Maybe I'll wait a couple of minutes.

All right, there there's no no new questions coming through. I would like to thank all of you who attended today.

It was a pleasure to have you on this call. Thank you, Ange, as well Angie as well, for attending even though you're not feeling well.

And, I will I shall close the meeting. Thank you very much.